Palvella’s QTORIN™ Gel Achieves Phase 3 SELVA Endpoint with Rapamycin Levels Under 2 ng/mL
QTORIN™ rapamycin gel met the primary endpoint in Phase 3 SELVA, with statistically significant benefits across primary and key secondary measures and systemic rapamycin levels under 2 ng/mL. A review in JoVA highlights genetic and clinical differences between microcystic and macrocystic lymphatic malformations and notes no FDA-approved therapies for microcystic disease.
1. Phase 3 SELVA Trial Success
The Phase 3 SELVA trial of QTORIN™ 3.9% rapamycin gel achieved its primary endpoint and demonstrated statistically significant improvements across all pre-specified primary, key secondary and secondary measures. Systemic rapamycin concentrations remained below 2 ng/mL at all timepoints, underscoring the gel’s tolerability and targeted delivery.
2. Journal Review Highlights LM Subtypes
A comprehensive review in the Journal of Vascular Anomalies delineates the distinct genetic and clinical profiles of microcystic versus macrocystic lymphatic malformations. The article emphasizes microcystic lesions’ diffuse small cyst networks, persistent lymphorrhea, infection risk and lack of FDA-approved treatments compared with more focal macrocystic disease.
3. Strategic and Development Implications
These combined findings reinforce Palvella’s strategy to develop QTORIN™ as a subtype-specific topical therapy for microcystic lymphatic malformations. With over 30,000 diagnosed US patients and no approved therapies, the data inform refined clinical trial design and bolster the company’s regulatory planning for QTORIN™ gel.